telmisartan has been researched along with Lung Injury, Acute in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 2 (100.00) | 2.80 |
| Authors | Studies |
|---|---|
| A Zezi, MY; Li, D; Wang, J; Zhou, X | 1 |
| Chen, L; Deng, M; Liang, Y; Ma, J; Wang, Y; Xu, J; Zhang, J; Zhang, L | 1 |
2 other study(ies) available for telmisartan and Lung Injury, Acute
| Article | Year |
|---|---|
Telmisartan ameliorates LPS-induced pneumonia in rats through regulation of the PPARγ/NF-κB pathway.
Topics: Acute Lung Injury; Animals; Cytokines; Inflammation; Lipopolysaccharides; Male; NF-kappa B; Pneumonia; PPAR gamma; Rats; Rats, Sprague-Dawley; Telmisartan | 2022 |
Telmisartan mitigates lipopolysaccharide (LPS)-induced production of mucin 5AC (MUC5AC) through increasing suppressor of cytokine signaling 1 (SOCS1).
Topics: Acute Lung Injury; Cell Line; Humans; Inflammation; Lipopolysaccharides; Mucin 5AC; Protective Agents; Signal Transduction; Suppressor of Cytokine Signaling 1 Protein; Telmisartan | 2021 |